Cytek Biosciences, Inc. CTKB
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -11.30% | -117.77% | -65.46% | -557.08% | -682.77% |
| Total Depreciation and Amortization | 1.63% | -0.10% | -2.46% | 11.02% | 8.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 112.48% | 82.00% | -19.48% | 994.97% | -66.47% |
| Change in Net Operating Assets | -65.31% | 634.01% | 197.06% | 36.82% | -209.33% |
| Cash from Operations | -14.19% | 1,165.74% | -2,088.80% | -138.61% | -129.48% |
| Capital Expenditure | -129.38% | -40.52% | -155.36% | -11.97% | 35.01% |
| Sale of Property, Plant, and Equipment | 7,000.00% | -86.96% | -81.82% | 2.09% | -95.24% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -101.86% | 162.15% | -342.67% | 98.34% | 232.10% |
| Cash from Investing | -109.52% | 142.78% | -386.49% | 97.10% | 219.68% |
| Total Debt Issued | -49.31% | -97.04% | 634.49% | -49.16% | 41,720.00% |
| Total Debt Repaid | -1,531.03% | -1,035.92% | 42.75% | -2,015.11% | -3.57% |
| Issuance of Common Stock | 635.77% | 22.82% | -46.15% | -36.41% | -6.80% |
| Repurchase of Common Stock | -85.92% | 96.01% | 97.78% | 96.71% | 98.83% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -128.90% | 68.72% | 134.48% | 66.32% | 116.06% |
| Foreign Exchange rate Adjustments | -81.32% | 165.80% | 152.61% | -6.98% | 189.71% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -137.36% | 141.26% | -630.93% | 96.18% | 214.06% |